MAGE-12 (114-127)

MAGE-12 (114-127) is a synthetic peptide fragment derived from the melanoma-associated antigen gene (MAGE) family, specifically corresponding to amino acid residues 114 to 127 of the MAGE-12 protein. As a member of the cancer-testis antigen group, MAGE-12 is predominantly expressed in various tumor tissues, with limited expression in normal adult tissues, making it a highly relevant target in tumor immunology and antigen-specific research. The defined sequence of this peptide enables precise investigations into antigen presentation, T-cell recognition, and epitope mapping, providing a robust tool for researchers exploring immune responses to tumor-associated antigens. Its biochemical properties and immunogenic potential have made it a valuable component in studies focused on tumor immunogenicity, peptide-MHC interactions, and the development of targeted molecular assays.

Epitope Mapping: MAGE-12 (114-127) is extensively utilized in epitope mapping studies to delineate immunodominant regions within the MAGE-12 protein. By employing this peptide in binding assays or T-cell activation experiments, researchers can identify specific amino acid sequences that are recognized by cytotoxic T lymphocytes or antibodies. This information is critical for understanding the molecular determinants of immune recognition in cancer contexts and supports the rational design of immunogenic epitopes for further functional analysis.

Antigen Presentation Analysis: The peptide serves as a model substrate in investigations of major histocompatibility complex (MHC) class I binding and antigen processing pathways. In vitro loading of MAGE-12 (114-127) onto antigen-presenting cells or artificial antigen-presenting systems enables the study of peptide-MHC interactions, peptide stability, and the efficiency of antigen presentation to T cells. These experiments provide mechanistic insights into how tumor antigens are processed and displayed, informing strategies for enhancing immune detection of malignancies.

T-Cell Activation Assays: Researchers deploy this peptide in functional assays to assess T-cell responses, such as proliferation, cytokine secretion, or cytotoxic activity, in the presence of antigen-presenting cells pulsed with MAGE-12 (114-127). These assays are instrumental in profiling the specificity and magnitude of T-cell responses against the MAGE-12 antigen, thereby supporting the selection and validation of immunogenic sequences for downstream applications in immunotherapy research or immune monitoring.

Peptide-Based Assay Development: The defined sequence and high specificity of this peptide fragment make it an ideal standard or control in the development and optimization of peptide-based immunoassays, including ELISPOT, ELISA, and flow cytometry-based detection methods. Incorporating MAGE-12 (114-127) into assay platforms allows for the calibration of detection systems, validation of assay sensitivity, and establishment of reproducible protocols for monitoring antigen-specific immune responses in experimental settings.

Structural and Biophysical Studies: The synthetic nature of MAGE-12 (114-127) enables its use in structural biology and biophysical research, such as investigating peptide-MHC binding affinities, conformational dynamics, or peptide stability under various conditions. These studies contribute to a deeper understanding of the molecular interactions governing antigen recognition and can inform the rational design of peptide analogs or mimetics with enhanced stability or binding characteristics for advanced research applications.

1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

2. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

5. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis